Adenosine and preconditioning revisited

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 2, 1999, Pages 92-99

  Miura, Tetsuji ^a   Tsuchida, Akihito ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenosine; Adenosine receptor; ATP sensitive potassium channel; Infaret size; Preconditioning; Protein kinase C

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; POTASSIUM CHANNEL; PROTEIN KINASE C;

BIOSYNTHESIS; CLASSIFICATION; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HUMAN; METABOLISM; REVIEW;

ADENOSINE; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL ISCHEMIA; POTASSIUM CHANNELS; PROTEIN KINASE C; RECEPTORS, PURINERGIC P1;

EID: 0033069798     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.03003.x     Document Type: Review

References (85)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
2. 1 adenosine receptors in rabbit heart. Circulation 1991; 84: 350-6.
3. Miura T, Iimura O. Infaret size limitation by ischemic preconditioning: Its phenomenological features and the key role of adenosine. Cardiovasc. Res. 1993; 27: 36-42.
4. Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ. Res. 1995; 77: 611-21.
5. Chien GL, Van Winkle DM. Naloxone blockade of myocardial ischemic preconditioning is stereoselective. J. Mol. Cell. Cardiol. 1996; 28: 1895-900.
6. Miki T, Cohen MV, Downey JM, Opioid receptor contributes to ischemic preconditioning through protein kinase C activation in rabbits. Mol. Cell. Biochem. 1998; 186: 3-12.
7. Nakano A, Miura T, Ura N, Suzuki K, Shimamoto K. Role of the angiotensin II type 1 receptor in preconditioning against infarction. Coron. Art. Dis. 1997; 8: 343-50.
8. Schrader J. Metabolism of adenosine and sites of production in the heart. In: Berne RM, Rall TW, Rubio R (eds). Regulatory Function of Adenosine. Martinus Nijhoff Publishers, Boston. 1983; Ch. 9.
9. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol. Rev. 1990; 70; 761-845.
10. Kroll K, Deckling UKM, Dreikorn K, Schrader J. Rapid turnover of the AMP-adenosine metabolic cycle in the guinea pig heart. Circ. Res. 1993; 73: 846-56.
11. Danish A, Pomerantz RW, Zogradides PC, Metting PJ. Contribution of cytosolic and membrane-bound 5′-nucleotidases to cardiac adenosine production. Am. J. Physiol. 1996; 271: H2162-7.
12. Chaudrey IH, Does ATP cross the cell plasma membrane? Yale. J. Biol. Med. 1982; 55: 1-10.
13. Burnstock G, Kennedy C. Purinergic receptors in the cardiovascular system. Prog. Pharmacol. 1986; 6: 111-32.
14. Raatikainen MJP, Peuhkurinen KJ, Hassinen IE. Contribution of endothelium and cardiomyocytes to hypoxia-induced adenosine release. J. Mol. Cell Cardiol. 1994; 26: 1069-80.
15. Borst MM, Schrader J. Adenine nucleotide release from isolated perfused guinea pig hearts and extracellular formation of adenosine. Circ. Res. 1991; 68: 797-806.
16. Miura T, Goto M, Miki T, Sakamoto J, Shimamoto K, Iimura O. Glibenclamide, an inhibitor of ATP sensitive potassium channels, blocks infaret size-limitation by preconditioning in rabbits anesthetized with xylazine/pentobarbital, but not with pentobarbital alone. J. Cardiovasc. Pharmacol. 1995; 25: 531-8.
17. Yamasaki K, Fujiwara H, Tanaka M et al. Preconditioning with 15-min ischemia extends myocardial infaret size after subsequent 30-minute ischemia in rabbits. Jpn. Circ. J. 1997; 61: 344-52.
18. Kitakaze M, Hori M, Takashima S, Sato H, Inoue M, Kamada T. Ischemic preconditioning increases adenosine release and 5′-nucleotidase activity during myocardial ischemia and reperfusion in dogs: Implication for myocardial salvage. Circulation 1993; 87: 208-15.
19. Kitakaze M, Hori M, Morioka T et al. Infaret size-limiting effect of ischemic preconditioning is blunted by inhibition of 5′-nucleotidase activity and attenuation of adenosinc release. Circulation 1994; 89: 1237-16.
20. 1-adrenoceptor activation mediates the infaret size-limiting effect of ischemic preconditioning through augmentation of 5′-nucleotidase activity. J. Clin. Invest. 1994; 93: 2197-205.
21. Przyklenk K, Zhao L, Kloner RA, Elliott GT. Cardioprotection with ischemic preconditioning and MLA. Role of adenosine-regulating enzyme? Am. J. Physiol. 1996; 271: H1004-14.
22. Przyklenk Hata K, Zhao L, Kloner RA, Elliott GT. Disparate effects of preconditioning and MLA on 5′-NT and adenosine levels during coronary occlusion. Am. J. Physiol. 1997; 273: H945-51.
23. Headrick JP, Willis RJ. 5′-Nucleotidase activity and adenosine formation in stimulated, hypoxic and underperfused rat heart. Biochem. J. 1989; 261: 541-50.
24. Askenasy N, Navon G. Intermittent ischemia: Energy metabolism, cellular volume regulation, adenosinc and insights into preconditioning. J. Mol. Cell. Cardiol. 1997; 29: 1717-30.
25. Ardell JL, Yang X-M, Barron RA, Downey JM, Cohen MV. Endogenous myocardial norepinephrine is not essential for ischemic preconditioning in rabbit heart. Am. J. Physiol. 1996; 270: H1078-84.
26. Miki T, Miura T, Bunger R, Suzuki K, Sakamoto J, Shimamoto K. Ecto-5′-nucleotidase is not required for ischemic preconditioning in rabbit myocardium in situ. Am. J. Physiol. 1998; 275: H1329-37.
27. Cohen MV, Liu Y, Downey JM. Activation of protein kinase C is critical to the protection of preconditioning. In: Wainwright CL, Parratt JR (eds). Myocardial Preconditioning. RG Landes Co., Georgetown. 1996; Ch. 11.
28. Thornton JD, Thornton CS, Downey JM. Effect of adenosine receptor blockade: Preventing preconditioning depends on time of initiation. Am. J. Physiol. 1993; 265: H504-8.
29. Miura T, Suzuki K, Shimamoto K, Timura O. Suppression of the degradation of adenine nucleotides during ischemia may not be a sufficient mechanism for infaret size limitation by preconditioning. Basic Res. Cardiol. 1996; 91: 425-32.
30. Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ. Res. 1990; 66: 913-31.
31. Suzuki K, Miura T, Miki T, Tsuchida A, Shimamoto K. Infaret-size limitation by preconditioning is enhanced by dipyridamole administered before but not after preconditioning: Evidence for the role of interstitial adenosine level during preconditioning as a primary determinant of cardioprotection. J. Cardiovasc. Pharmacol. 1998; 31: 1-9.
32. Fredholm BB, Abbracchio MP, Burnstock G et al. Nomenclature and classification of purinoceptors. Pharmacol, Rev. 1994; 46: 143-56.
33. Kohl C, Linck B, Schmitz W, Scholz H, Scholz J, Toth M. Effects of carbachol and (-)-N6-phenylisopropyladenosine on myocardial inositol phosphate content and force of contraction. Br. J. Pharmacol 1990; 101: 829-34.
34. 1 adenosine receptors expressed in CHO-cells couple to adenylyl cyclase and to phospholipase C, Naunyn Schmiedebergs Arch. Pharmacol. 1994; 350: 49-56.
35. p. Biochem. Soc. Trans. 1991; 19: 299-302.
36. 3 adenosine receptor. Proc. Natl Acad. Sci. USA 1992, 89: 7432-6.
37. 3 receptors. J. Pharmacol. Exp. Ther. 1997; 280: 122-8.
38. Tsuchida A, Miura T, Miki T, Shimamoto K, Iimura O. Role of adenosine receptor activation in myocardial infaret size limitation by ischaemic preconditioning. Cardiovasc. Res. 1992; 26: 456-61.
39. 1-selective adenosine analogues protects the heart against infarction. Circulation 1992; 85: 659-65.
40. 3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc. Res. 1994; 28: 1057-61.
41. 3 receptors during prolonged simulated ischemia. Am. J. Physiol. 1997; 273: H501-5.
42. 3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc. Res. 1997; 33: 410-15.
43. Rice PJ, Armstrong SC, Ganote CE. Concentration response relationships for adenosine agonists during preconditioning of rabbit cardiomyocytes. J. Mol. Cell. Cardiol. 1996; 28: 1355-65.
44. Ytrehus K, Liu Y, Downey JM, Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am. J. Physiol. 1994; 266: H1145-52.
45. 1 receptor activation is abolished by protein kinase C inhibitors in the rabbit. Cardiovasc. Res. 1995; 29: 682-8.
46. Shukla SD, Halenda SP. Phospholipase D in cell signaling and its relationship to phospholipase C. Life Sci. 1991; 48: 851-66.
47. Cohen MV, Liu Y, Liu GS et al. Phospholipase D plays a role in ischemic preconditioning in rabbit heart. Circulation 1996; 94: 1713-18.
48. Tosaki A, Maulik N, Cordis G, Trifan OC, Popescu LM, Das DK. Ischemic preconditioning triggers phospholipase D signaling in rat heart. Am. J. Physiol. 1997; 273: H1861-6.
49. Przyklenk K, Sussman MA, Sinikhovich BZ, Kloner RA. Docs ischemic preconditioning trigger translocation of protein kinase C in the canine model? Circulation 1995; 92: 1546-57.
50. Simkhovich BZ, Przyklenk K, Hale SL, Patterson M, Kloner RA. Direct evidence that ischemic preconditioning does not cause protein kinase C: translocation in rabbit heart. Cardiovasc. Res. 1996; 32: 1064-70.
51. Armstrong SC, Hoover OB, Delacey MH, Ganote CE. Translocation of PKC, protein phosphatase inhibition and preconditioning of rabbit cardiomyocytes. J. Mol. Cell. Cardiol. 1996; 28: 1479-92.
52. Mitchell MB, Meng X, Brown JM, Harken AH, Banerjee A. Preconditioning of isolated rat heart is mediated by protein kinase C. Circ. Res. 1995; 76: 73-81.
53. Kitakaze M, Node K, Minamino T et al. Role of activation of protein kinase C in the infaret size-limiting effect of ischemic preconditioning through activation of ecto-5′-nucleotidase. Circulation 1996; 93: 781-91.
54. Ping P, Zhang J, Qiu Y et al. Ischemic preconditioning induces selective iranslocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ. Res. 1997; 81: 404-14.
55. 1-Adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ. Res. 1994; 75: 576-85.
56. Speechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C. Its role in ischemic preconditioning in the rat. Circ. Res. 1994; 75: 586-90.
57. Vahlhause C, Schultz R, Post H, Onallah R, Heusch G. No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine, Circ Res. 1996; 79: 407-14.
58. Miura T, Miura T, Kawamura S et al. Effect of protein kinase C inhibitors on cardioprotection by ischemic preconditioning depends on the number of preconditioning episodes. Cardiovasc. Res. 1998; 37: 700-9.
59. Vahlhous C, Schultz R, Post H, Rose J, Heusch G. Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs. J. Mol. Cell. Cardiol. 1998; 30: 197-209.
60. +-channel. News Physiol. Sci. 1997; 12: 255-63.
61. + channel opening drugs. Am. J. Physiol. 1995; 269: C525-45.
62. + channels, A possible mechanistic link to ischemic preconditioning. Circ. Res. 1996; 79: 399-406.
63. + currents by protein kinase C and adenosine: Implications for ischemic preconditioning. Circ. Res. 1996; 78: 443-54.
64. + channels protect the myocardium against ischemia/reperfusion damage. Circ. Res. 1991; 69: 571-81.
65. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ. Res. 1992; 70: 223-33.
66. ATP channel. Am. J. Physiol. 1994; 266: 11829-39.
67. Toombs CF, Moore TL, Shebuski RJ. Limitation of infaret size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc. Res. 1993; 27: 617-22.
68. Liu Y, Downey JM. Ischemic preconditioning protects against infarction in rat heart. Am. J. Physiol. 1992; 263 H1107-12.
69. Schultz JEJ, Yao Z, Cavero I, Gross GJ. Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. Am. J. Physiol. 1997; 272: H2607-15.
70. ATP blocker sodium 5-hydroxydecanoate does not abolish preconditioning in isolated rat hearts. Eur. J. Pharmacol. 1995; 277: 271-4.
71. ATP channels. Am. J. Physiol. 1997; 272; H334-42.
72. Shattock MJ, Lawson CS, Hearse DJ, Downey JM. Electrophysiological characteristics of repetitive ischemic preconditioning in the heart. J. Mol. Cell. Cardiol. 1996; 28: 1339-47.
73. + channels in guinea pig ventricular cells and its modulation by glycolysis. Cardiovasc Res. 1997; 35: 273-82.
74. ATP) channels, J. Mol. Cell. Cardiol. 1995; 27: A142 (Abstract).
75. ATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infaret size in dogs. Circulation 1994; 89: 1769-75.
76. + blocker dofetilide. Am. J. Physiol. 1996; 271: H1207-14.
77. + channels. Possible mechanism of cardioprotection. Circ. Res. 1997; 81: 1072-82.
78. + channels by protein kinase C. Circ. Res. 1998; 83: 110-14.
79. Kida M, Fujiwara H, Ishida M et al. Ischemic preconditioning preserves creatine phosphate and intracellular pH. Circulation 1991; 84: 2495-503.
80. Gottlieb RA, Gruol DL, Zhu JY, Engler RL. Preconditioning in rabbit cardiomyocytes. Role of pH, vacuolar proton ATPase, and apoptosis. J. Clin. Invent. 1996; 97: 2391-8.
81. Ramasamy R, Liu H, Anderson S, Landmark J, Schaefer S. Ischemic preconditioning stimulates sodium and proton transport in isolated rat hearts. J. Clin. Invest, 1995; 96; 1464-72.
82. 2+ overload in reperfused ischemic myocardium. Annu. Rev. Physiol. 1990; 52: 543-59.
83. + exchange in ischemia reperfusion. Basic Res. Cardiol. 1996; 91: 191-202.
84. Bugge E, Ytrehus K. Inhibition of sodium-hydrogen exchange reduces infaret size in the isolated rat heart: A protective additive to ischaemic preconditioning. Cardiovasc. Res. 1995; 29; 269-74.
85. + exchange inhibitor, Hoe642: Difference from preconditioning in the role of protein kinase C. J. Am. Coll. Cardiol. 1997; 29; 693-701.